Phenotype-based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2019 Jul 13

PMID 31296572

Citations 81

Authors

Heikki Kuusanmaki

Aino-Maija Leppa

Petri Polonen

Mika Kontro

Olli Dufva

Debashish Deb

Bhagwan Yadav

Oscar Bruck

Ashwini Kumar

Hele Everaus

Bjorn T Gjertsen

Merja Heinaniemi

Kimmo Porkka

Satu Mustjoki

Caroline A Heckman

Affiliations

Soon will be listed here.

Citing Articles

Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34 Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/Ferroptosis.

Selheim F, Aasebo E, Reikvam H, Bruserud O, Hernandez-Valladares M Proteomes. 2025; 13(1).

PMID: 39982321 PMC: 11843884. DOI: 10.3390/proteomes13010011.

BH3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism.

Yee C, Saxena K, Ryu E, Hung S, Singh S, Zhang Q Res Sq. 2024; .

PMID: 39711535 PMC: 11661303. DOI: 10.21203/rs.3.rs-5307127/v1.

Decoding Acute Myeloid Leukemia: A Clinician's Guide to Functional Profiling.

Iyer P, Jasdanwala S, Wang Y, Bhatia K, Bhatt S Diagnostics (Basel). 2024; 14(22).

PMID: 39594226 PMC: 11593197. DOI: 10.3390/diagnostics14222560.

Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.

Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo C, Rausch C Blood Cancer Discov. 2024; 6(1):23-37.

PMID: 39565177 PMC: 11707511. DOI: 10.1158/2643-3230.BCD-24-0171.

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.

Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G Nature. 2024; 636(8041):241-250.

PMID: 39478230 PMC: 11618090. DOI: 10.1038/s41586-024-08137-x.

References

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth R, Yang H . A New Bliss Independence Model to Analyze Drug Combination Data. J Biomol Screen. 2014; 19(5):817-21. DOI: 10.1177/1087057114521867. View

Konopleva M, Pollyea D, Potluri J, Chyla B, Hogdal L, Busman T . Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016; 6(10):1106-1117. PMC: 5436271. DOI: 10.1158/2159-8290.CD-16-0313. View

Glaser S, Lee E, Trounson E, Bouillet P, Wei A, Fairlie W . Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012; 26(2):120-5. PMC: 3273836. DOI: 10.1101/gad.182980.111. View

Polonen P, Mehtonen J, Lin J, Liuksiala T, Hayrynen S, Teppo S . Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019; 79(10):2466-2479. DOI: 10.1158/0008-5472.CAN-18-2970. View

Mehtonen J, Polonen P, Hayrynen S, Dufva O, Lin J, Liuksiala T . Data-driven characterization of molecular phenotypes across heterogeneous sample collections. Nucleic Acids Res. 2019; 47(13):e76. PMC: 6648337. DOI: 10.1093/nar/gkz281. View

Tyner J, Yang W, Bankhead 3rd A, Fan G, Fletcher L, Bryant J . Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2012; 73(1):285-96. PMC: 3537897. DOI: 10.1158/0008-5472.CAN-12-1906. View

Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C . Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464. PMC: 5754190. DOI: 10.1056/NEJMoa1614359. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

10.

Kurtz S, Eide C, Kaempf A, Khanna V, Savage S, Rofelty A . Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017; 114(36):E7554-E7563. PMC: 5594650. DOI: 10.1073/pnas.1703094114. View

11.

Bogenberger J, Kornblau S, Pierceall W, Lena R, Chow D, Shi C . BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014; 28(8):1657-65. PMC: 4131248. DOI: 10.1038/leu.2014.44. View

12.

Kontro M, Kumar A, Majumder M, Eldfors S, Parsons A, Pemovska T . HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 2016; 31(2):301-309. DOI: 10.1038/leu.2016.222. View

13.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A . Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-29. DOI: 10.1158/2159-8290.CD-13-0350. View

14.

Faderl S, Harris D, Van Q, Kantarjian H, Talpaz M, Estrov Z . Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003; 102(2):630-7. DOI: 10.1182/blood-2002-06-1890. View

15.

Dietrich S, Oles M, Lu J, Sellner L, Anders S, Velten B . Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2017; 128(1):427-445. PMC: 5749541. DOI: 10.1172/JCI93801. View

16.

Panoskaltsis N, Reid C, Knight S . Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia. 2003; 17(4):716-30. DOI: 10.1038/sj.leu.2402835. View

17.

van der Schoot C, Jansen P, Poorter M, WESTER M, von dem Borne A, Aarden L . Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood. 1989; 74(6):2081-7. View

18.

Niu X, Wang G, Wang Y, Caldwell J, Edwards H, Xie C . Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014; 28(7):1557-60. PMC: 4090260. DOI: 10.1038/leu.2014.72. View

19.

Tauro S . The blind men and the AML elephant: can we feel the progress?. Blood Cancer J. 2016; 6:e424. PMC: 4916302. DOI: 10.1038/bcj.2016.33. View

20.

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View